Shire Buys FerroKin BioSciences To Further Hematology Strategy
Shire gains an iron chelator in Phase II development in exchange for $100 million upfront and post-closing milestones of $225 million.
Shire gains an iron chelator in Phase II development in exchange for $100 million upfront and post-closing milestones of $225 million.